JPRN-UMIN000014017招募中2 期
A randomized controlled phase II/III study comparing EBD combined with steroid to RIC combined with steroid for refractory anastomotic stricture after esophagectomy (JCOG1207: RICS study) - A randomized controlled phase II/III study comparing EBD combined with steroid versus RIC combined with steroid for refractory anastomotic stricture after esophagectomy (JCOG1207: RICS study)
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 130 人开始时间: 2014年5月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Active infection requiring systemic therapy 2) Body temperature >=38 degrees Celsius 3) Pregnancy, possible pregnancy within 28 days after delivery or breastfeeding 4) Psychiatric disease 5) Patients requiring systemic steroid medication 6) Patients requiring continuous anticoagulant or antiplatelet drug 7) Poorly controlled hypertension 8) Unstable angina within 3 weeks, or with a history of myocardial infarction within 6 months
研究者
相似试验
已完成
2 期
A phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis (JCOG1310, PRECIOUS trial)ower rectal cancer with suspected lateral pelvic node metastasisJPRN-UMIN000017603Japan Clinical Oncology Group (JCOG)330
进行中（未招募）
1 期
Study of efficacy and safety of NIS793 in combination with standard of care (SOC) chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)Pancreatic ductal adenocarcinomaMedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2021-000591-10-ITOVARTIS PHARMA AG490
进行中（未招募）
1 期
Study of efficacy and safety of NIS793 in combination with standard of care (SOC) chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)Pancreatic ductal adenocarcinomaMedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2021-000591-10-HUovartis Pharma AG490
进行中（未招募）
1 期
Study of efficacy and safety of NIS793 in combination with standard of care (SOC) chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)Pancreatic ductal adenocarcinomaMedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2021-000591-10-SEovartis Pharma AG490
进行中（未招募）
1 期
Study of efficacy and safety of NIS793 in combination with standard of care (SOC) chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)EUCTR2021-000591-10-DEovartis Pharma AG490